Amicus Therapeutics, Inc. (FOLD) Tops Q1 EPS by 1c; Guides In-line
Tweet
Share
E-mailGet Alerts FOLD Hot Sheet
Price: $14.49 --0%
Financial Fact:
Restructuring charges: 11K
Today's EPS Names:
PLCE, COE, JVA, More
Financial Fact:
Restructuring charges: 11K
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q1 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.52 million.
Amicus continues to expect full-year 2012 operating expenses will total between $37 million to $43 million (Consensus is $40.26 mln), net of anticipated cost sharing and milestones related to the GSK collaboration. Amicus and GSK equally shared development costs for migalastat HCl (monotherapy and co-administration) in 2011, and GlaxSmithKline (NYSE: GSK) is responsible for 75% of these costs in 2012 and beyond, subject to annual and aggregate caps. Amicus is also eligible to receive up to a total of $170 million in development, regulatory and commercial milestones as part of the Fabry collaboration with GSK.
For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.
Amicus continues to expect full-year 2012 operating expenses will total between $37 million to $43 million (Consensus is $40.26 mln), net of anticipated cost sharing and milestones related to the GSK collaboration. Amicus and GSK equally shared development costs for migalastat HCl (monotherapy and co-administration) in 2011, and GlaxSmithKline (NYSE: GSK) is responsible for 75% of these costs in 2012 and beyond, subject to annual and aggregate caps. Amicus is also eligible to receive up to a total of $170 million in development, regulatory and commercial milestones as part of the Fabry collaboration with GSK.
For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
- Independent Bank receives regulatory approval for HCB Financial acquisition
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
